CO2023018652A2 - Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos - Google Patents

Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos

Info

Publication number
CO2023018652A2
CO2023018652A2 CONC2023/0018652A CO2023018652A CO2023018652A2 CO 2023018652 A2 CO2023018652 A2 CO 2023018652A2 CO 2023018652 A CO2023018652 A CO 2023018652A CO 2023018652 A2 CO2023018652 A2 CO 2023018652A2
Authority
CO
Colombia
Prior art keywords
analogues
fluorinated
methods
tryptamine compounds
tryptamine
Prior art date
Application number
CONC2023/0018652A
Other languages
English (en)
Spanish (es)
Inventor
Jason Wallach
Michael Dybek
Original Assignee
Saint Josephs Univ
Compass Pathfinder Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Saint Josephs Univ, Compass Pathfinder Ltd filed Critical Saint Josephs Univ
Publication of CO2023018652A2 publication Critical patent/CO2023018652A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C07D209/16—Tryptamines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D209/26—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an acyl radical attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CONC2023/0018652A 2021-06-02 2023-12-29 Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos CO2023018652A2 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163195943P 2021-06-02 2021-06-02
US202163288313P 2021-12-10 2021-12-10
PCT/US2022/032000 WO2022256554A1 (en) 2021-06-02 2022-06-02 Fluorinated tryptamine compounds, analogues thereof, and methods using same

Publications (1)

Publication Number Publication Date
CO2023018652A2 true CO2023018652A2 (es) 2024-01-25

Family

ID=84324579

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2023/0018652A CO2023018652A2 (es) 2021-06-02 2023-12-29 Compuestos de triptamina fluorada, análogos de estos y métodos de uso de estos

Country Status (11)

Country Link
US (1) US20240286998A1 (cg-RX-API-DMAC7.html)
EP (1) EP4347559A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024523822A (cg-RX-API-DMAC7.html)
KR (1) KR20240017363A (cg-RX-API-DMAC7.html)
AU (1) AU2022287013A1 (cg-RX-API-DMAC7.html)
BR (1) BR112023025340A2 (cg-RX-API-DMAC7.html)
CA (1) CA3220850A1 (cg-RX-API-DMAC7.html)
CO (1) CO2023018652A2 (cg-RX-API-DMAC7.html)
IL (1) IL308944A (cg-RX-API-DMAC7.html)
MX (1) MX2023014437A (cg-RX-API-DMAC7.html)
WO (1) WO2022256554A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
EP4396162A4 (en) 2021-09-03 2025-11-12 Alexander Shulgin Res Institute Inc ASYMMETRIC ALLYL TRYPTAMINES
WO2023147424A1 (en) * 2022-01-27 2023-08-03 Terran Biosciences, Inc. Salts and solid forms of n-ethyl-2-(5-fluoro-1h-indol-3-yl)- n-methylethan-1-amine
US12157722B1 (en) * 2023-08-03 2024-12-03 Gilgamesh Pharmaceuticals, Inc. Crystalline hydrochloride salts of N-ethyl-2-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
US12129234B1 (en) 2023-08-03 2024-10-29 Gilgamesh Pharmaceuticals, Inc. Crystalline salts of N-ethyl-(5-fluoro-1H-indol-3-yl)-N-methylethan-1-amine
CN121866243A (zh) * 2023-09-07 2026-04-14 耶路撒冷希伯来大学伊森姆研究发展有限公司 致幻化合物、其制备方法及其用途
WO2025104491A1 (en) * 2023-11-14 2025-05-22 Mindset Pharma Inc. Indole derivatives as serotonergic agents useful for the treatment of disorders related thereto

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0848706B1 (en) * 1995-06-06 2003-02-05 Schering Corporation Substituted benzene-fused heterocyclics as neurokinin antagonists
DE19615232A1 (de) * 1996-04-18 1997-10-23 Merck Patent Gmbh Neue Carbamoylderivate und deren Verwendung als 5-HT ¶1¶¶A¶-Antagonisten
US6100291A (en) * 1998-03-16 2000-08-08 Allelix Biopharmaceuticals Inc. Pyrrolidine-indole compounds having 5-HT6 affinity
AR021509A1 (es) * 1998-12-08 2002-07-24 Lundbeck & Co As H Derivados de benzofurano, su preparacion y uso
US6800637B2 (en) * 2002-09-12 2004-10-05 Wyeth Antidepressant indolealkyl derivatives of heterocycle-fused benzodioxan methylamines
JP7273731B2 (ja) * 2017-02-09 2023-05-15 カームテック、エルエルシー シロシビン誘導体を含む組成物及び方法
WO2019222552A1 (en) * 2018-05-16 2019-11-21 University Of Florida Research Foundation Methods and compositions for substituted 2,5-diketopiperazine analogs
GB201907871D0 (en) * 2019-06-03 2019-07-17 Small Pharma Ltd Therapeutic compositions
AU2021215709A1 (en) * 2020-02-04 2022-09-01 Mindset Pharma Inc. 3-pyrrolidine-indole derivatives as serotonergic psychedelic agents for the treatment of CNS disorders
LT4084791T (lt) * 2020-02-18 2025-02-25 Gilgamesh Pharmaceuticals, Inc. Specifiniai triptaminai, skirti nuotaikos sutrikimams gydyti
MX2023002557A (es) * 2020-09-01 2023-05-29 Enveric Biosciences Canada Inc Derivados de psilocibina halogenada y metodos de uso.
CA3192617A1 (en) * 2020-09-20 2022-03-24 Matthew BAGGOTT Advantageous tryptamine compositions for mental disorders or enhancement
US20240051978A1 (en) * 2020-12-07 2024-02-15 Mindset Pharma Inc. 3-cyclic amine-indole derivatives as serotonergic agents for the treatment of cns disorders

Also Published As

Publication number Publication date
IL308944A (en) 2024-01-01
JP2024523822A (ja) 2024-07-02
MX2023014437A (es) 2024-03-08
US20240286998A1 (en) 2024-08-29
EP4347559A1 (en) 2024-04-10
CA3220850A1 (en) 2022-12-08
EP4347559A4 (en) 2025-04-09
AU2022287013A1 (en) 2023-12-07
KR20240017363A (ko) 2024-02-07
WO2022256554A1 (en) 2022-12-08
BR112023025340A2 (pt) 2024-02-20

Similar Documents

Publication Publication Date Title
MX2023014437A (es) Compuestos de triptamina fluorada, análogos de estos y métodos de uso estos.
CL2019002574A1 (es) Moduladores de la expresión de pcsk9.
UY39135A (es) ANTICUERPOS MONOCLONALES HUMANOS DIRIGIDOS CONTRAEL CORONAVIRUS 2 DEL SÍNDROME RESPIRATORIO AGUDO GRAVE (SARS-CoV-2)
CO2020001220A2 (es) Compuestos, composiciones y métodos
ECSP21026021A (es) Moduladores de la expresión de pnpla3
CO2021008816A2 (es) Moduladores de trex1
MX2021015545A (es) Moduladores de cot y metodos de uso de estos.
CL2020003447A1 (es) Composiciones y métodos para el tratamiento de enfermedades o condiciones relacionadas con inflamasomas
CL2020003010A1 (es) Moduladores de la expresión de apol1
MX2019000428A (es) Agentes y metodos para la prevencion o el tratamiento de infecciones por h. pylori.
CL2020002101A1 (es) Formulaciones de liberación sostenida de ácido bempedoico.
CO2020008769A2 (es) Moduladores de la expresión dnm2
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CO2022000266A2 (es) Inhibidores de enzimas
CO2021007006A2 (es) Moduladores de la expresión de irf5
MX2024002913A (es) Anticuerpos anti-siglec-6 y metodos de uso de los mismos.
CL2020001252A1 (es) Métodos de uso y composiciones que contienen dulaglutida.
PE20221009A1 (es) Sintesis de un inhibidor de calicreina plasmatica a escala de proceso
DOP2021000215A (es) Tratamiento de la cefalea usando anticuerpo anti-cgrp
CL2024000881A1 (es) Estructuras derivadas de tn3 específicas de cd40l para tratamiento y prevención del síndrome de sjogren
CL2022003206A1 (es) Compuestos derivados de quinolona y su uso para el tratamiento del cáncer (div. sol. 202102501)
AR118532A1 (es) Composiciones de limpieza
CO2020003134A2 (es) Moduladores de la expresión de enac
PE20070809A1 (es) Composicion veterinaria que comprende closantel
MX2020002485A (es) Metodos de uso del dantroleno para tratar la exposicion a agente nervioso.